title: Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action.
abstract: A recent investigation of the effect of different antiretroviral drug classes on first phase dynamics of HIV RNA plasma virus levels has indicated that drugs acting at stages closer to viral production, such as the integrase inhibitor raltegravir, can produce a steeper first phase decay slope that may not be due to drug efficacy. Moreover it was found that for most drug classes the first phase transitions from a faster (phase IA) to a slightly slower decay region (phase IB) before the start of the usual second phase. Neither of these effects has been explained to date. We use a mathematical model that incorporates the different stages of the HIV viral life cycle in CD4+ T cells: viral entry, reverse transcription, integration, and viral production, to investigate the intracellular HIV mechanisms responsible for these complex plasma virus decay dynamics. We find differences in the phase IA slope across drug classes arise from a higher death rate of cells when they enter the productively infected stage post-integration, with a half-life of approximately 8 hours in this stage, whereas cells in earlier stages of the infection cycle have half-lives similar to uninfected cells. This implies any immune clearance is predominantly limited to the productive infection stage. We also show that the slowing of phase IA to phase IB at day 2 to 4 of monotherapy, depending on drug class, is a result of new rounds of infection. The level at which this slowing occurs is a better indicator of drug efficacy than the slope of the initial decay.
authors.affiliation: School of Mathematics and Statistics, University of New South Wales, Sydney, New South Wales, Australia.
authors.forename: James B
authors.initials: JB
authors.lastname: Gilmore
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Kelleher
authors.forename: David A
authors.initials: DA
authors.lastname: Cooper
authors.forename: John M
authors.initials: JM
authors.lastname: Murray
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000821:virology*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D008954:Models, Biological; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents
references.citation: Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7247-51
references.pmid: 8692977
references.citation: J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):405-12
references.pmid: 11391159
references.citation: AIDS. 2010 Mar 13;24(5):707-16
references.pmid: 20087154
references.citation: J Theor Biol. 2004 Jan 7;226(1):95-109
references.pmid: 14637059
references.citation: Math Biosci. 1998 Sep;152(2):143-63
references.pmid: 9780612
references.citation: Cell. 2010 Nov 24;143(5):789-801
references.pmid: 21111238
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4832-7
references.pmid: 18362342
references.citation: Nat Med. 1998 Nov;4(11):1302-7
references.pmid: 9809555
references.citation: Nat Med. 2005 Nov;11(11):1170-2
references.pmid: 16205738
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1047-54
references.pmid: 20038621
references.citation: AIDS. 2006 Aug 22;20(13):1721-6
references.pmid: 16931936
references.citation: PLoS Comput Biol. 2010 Mar 26;6(3):e1000720
references.pmid: 20361047
references.citation: Lancet. 1999 Nov 20;354(9192):1782-5
references.pmid: 10577640
references.citation: J Clin Pharmacol. 1998 Aug;38(8):736-43
references.pmid: 9725550
references.citation: AIDS. 2007 Nov 12;21(17):2315-21
references.pmid: 18090280
references.citation: Nature. 1995 Jan 12;373(6510):123-6
references.pmid: 7816094
references.citation: J Virol. 2011 Oct;85(20):10798-805
references.pmid: 21835801
references.citation: J Virol. 1989 Sep;63(9):3708-13
references.pmid: 2760980
references.citation: Nature. 1995 Jan 12;373(6510):117-22
references.pmid: 7529365
references.citation: Curr Opin Immunol. 2012 Feb;24(1):71-6
references.pmid: 22341517
references.citation: Biosystems. 2009 Jan;95(1):1-6
references.pmid: 18706970
references.citation: J Immunol. 2000 Dec 1;165(11):6437-46
references.pmid: 11086083
references.citation: Immunol Rev. 2007 Apr;216:164-75
references.pmid: 17367342
references.citation: Nature. 1997 May 8;387(6629):188-91
references.pmid: 9144290
references.citation: Science. 1996 Mar 15;271(5255):1582-6
references.pmid: 8599114
references.citation: Virology. 2007 Feb 5;358(1):119-35
references.pmid: 16979207
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6971-6
references.pmid: 9192676
references.citation: Proc Biol Sci. 2001 Apr 22;268(1469):847-54
references.pmid: 11345331
references.citation: J Virol. 2003 Apr;77(8):5037-8
references.pmid: 12663814
references.citation: Math Biosci. 2000 Feb;163(2):201-15
references.pmid: 10701304
references.citation: J Immunol. 2007 Mar 1;178(5):2746-54
references.pmid: 17312117
references.citation: Math Biosci. 2002 Jul-Aug;179(1):73-94
references.pmid: 12047922
references.citation: Nat Med. 1999 Oct;5(10):1099-104
references.pmid: 10502799
references.citation: Antivir Ther. 2004 Apr;9(2):237-46
references.pmid: 15134186
references.citation: J Exp Med. 2003 Dec 15;198(12):1909-22
references.pmid: 14676302
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7
references.pmid: 10737796